A comprehensive New England Journal of Medicine analysis reveals that US states are increasingly taking the lead in advancing psychedelic-assisted therapies, even as federal restrictions remain in place. Fifteen or more states have enacted or are actively considering psychedelic therapy legislation, with regulatory frameworks ranging from pilot programs to full therapeutic access approvals.
Oregon’s pioneering Psilocybin Services Program and Colorado’s psychedelic decriminalization efforts demonstrate how states are navigating the legal gray area between state-level innovation and federal controlled substance classifications. These initiatives focus primarily on psilocybin for treatment-resistant depression and MDMA for post-traumatic stress disorder, incorporating rigorous safety protocols and specialized provider training.
The analysis underscores growing tension between state-level therapeutic advancement and federal policy constraints, with state innovation potentially catalyzing broader national policy reform in mental health treatment.
Was this article helpful?
